Research across Cardiomyopathy
Related studies from across the Cardiomyopathy family.
Part of Cardiomyopathy
2 published articles · Updated continuously
5 trials tracked for Hypertrophic obstructive cardiomyopathy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 105 citations.
Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Mavacamten has demonstrated efficacy in reducing LVOT peak gradients in patients with hypertrophic obstructive cardiomyopathy. At week 30, a significant proportion of participants achieved a Valsalva LVOT peak gradient of < 30 mmHg 1 and < 50 mmHg 1.
Clinical improvements associated with mavacamten include a measurable reduction in the severity of HCM symptoms as measured by the HCMSQ score 2 and an improvement in health-related quality of life (KCCQ score) at week 30 2. Additionally, approximately 63.2% of patients treated with mavacamten showed at least one class improvement in their New York Heart Association (NYHA) functional class by week 30 3.
AI synthesis of 5 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Cardiomyopathy family.